Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CDTTW
Upturn stock ratingUpturn stock rating

Conduit Pharmaceuticals Inc. (CDTTW)

Upturn stock ratingUpturn stock rating
$0.02
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/27/2025: CDTTW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -64.29%
Avg. Invested days 6
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/27/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 2
52 Weeks Range 0.01 - 0.05
Updated Date 05/21/2025
52 Weeks Range 0.01 - 0.05
Updated Date 05/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -168.26%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 552357
Shares Outstanding -
Shares Floating 552357
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Conduit Pharmaceuticals Inc.

stock logo

Company Overview

overview logo History and Background

Conduit Pharmaceuticals Inc. was formed to identify, acquire, develop, and commercialize late-stage drug candidates. The company aims to accelerate the development and approval of innovative therapies for unmet medical needs.

business area logo Core Business Areas

  • Drug Development: Focuses on the clinical development and regulatory approval of acquired drug candidates.
  • Commercialization: Involves the marketing and sale of approved pharmaceutical products.
  • Acquisition and Licensing: Identifies and secures rights to promising late-stage drug candidates through acquisitions or licensing agreements.

leadership logo Leadership and Structure

Details about the leadership team and organizational structure are not readily available in public sources.

Top Products and Market Share

overview logo Key Offerings

  • AZD1656 (Bemcentinib): This is one of Conduit's lead assets and is an investigational oral selective inhibitor of tyrosine kinase Tyro3, Axl, and Mer (TAM). Details regarding its market share and competition are not available.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development.

Positioning

Conduit Pharmaceuticals Inc. aims to differentiate itself by focusing on late-stage drug candidates, potentially reducing development risk and accelerating time to market.

Total Addressable Market (TAM)

The specific TAM depends on the therapeutic areas targeted by Conduit's drug candidates and is not precisely defined in publicly available information. However, the broader pharmaceutical market is valued in the hundreds of billions of dollars annually.

Upturn SWOT Analysis

Strengths

  • Focus on late-stage assets
  • Experienced management team (if available)
  • Potential for accelerated development timelines

Weaknesses

  • Dependence on successful acquisition and development of assets
  • High regulatory risk
  • Limited commercial infrastructure

Opportunities

  • Acquire promising drug candidates at favorable terms
  • Partner with larger pharmaceutical companies for commercialization
  • Expand into new therapeutic areas

Threats

  • Failure of clinical trials
  • Regulatory setbacks
  • Competition from established pharmaceutical companies

Competitors and Market Share

competitor logo Key Competitors

  • Big Pharma names like Pfizer (PFE), Novartis (NVS) or AstraZeneca (AZN) depending on the specific therapy areas they target. It also depends on who makes competing tyrosine kinase inhibitor drugs.

Competitive Landscape

Conduit Pharmaceuticals Inc. faces significant competition from established pharmaceutical companies with greater resources and expertise. The company's success depends on its ability to efficiently acquire, develop, and commercialize innovative therapies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data is limited due to the company's recent formation.

Future Projections: Future growth projections depend on the successful development and commercialization of its drug candidates. Analyst estimates are not widely available.

Recent Initiatives: Recent strategic initiatives likely include the acquisition and advancement of drug candidates, securing financing, and building a team.

Summary

Conduit Pharmaceuticals Inc. is a pharmaceutical company focused on acquiring and developing late-stage drug candidates. Its success hinges on the successful clinical trials and regulatory approvals of its lead assets. Its focus on late-stage assets offers the potential for quicker market entry, but the company faces significant competition and regulatory hurdles. The company will need to strategically manage its pipeline and secure partnerships to maximize its growth potential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Press Releases
  • SEC Filings (where available)
  • Third-party pharmaceutical industry reports

Disclaimers:

The information provided is based on publicly available sources and is not intended as investment advice. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Conduit Pharmaceuticals Inc.

Exchange NASDAQ
Headquaters Naples, FL, United States
IPO Launch date 2023-09-25
Founder, CEO & Director Dr. Andrew Regan
Sector Healthcare
Industry Biotechnology
Full time employees 6
Full time employees 6

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.